Opendata, web and dolomites

TREGeneration SIGNED

Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TREGeneration" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.tregeneration.eu
 Total cost 5˙899˙250 €
 EC max contribution 5˙899˙250 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-single-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 1˙792˙894.00
2    KLINIKUM DER UNIVERSITAET REGENSBURG DE (REGENSBURG) participant 1˙348˙823.00
3    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 741˙335.00
4    AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO S. ORSOLA MALPIGHI IT (BOLOGNA) participant 617˙080.00
5    UNIVERSITE DE LIEGE BE (LIEGE) participant 496˙200.00
6    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) participant 290˙420.00
7    ALACRIS THERANOSTICS GMBH DE (BERLIN) participant 277˙500.00
8    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 246˙077.00
9    GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG DE (MUENCHEN) participant 88˙919.00

Map

 Project objective

Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy. The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells. Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.

 Deliverables

List of deliverables.
Twitter, Facebook, LinkedIn, Account Setup Websites, patent fillings, videos etc. 2019-05-08 12:01:41
Launch of website Websites, patent fillings, videos etc. 2019-05-08 12:01:37
Individualized press release for every partner Websites, patent fillings, videos etc. 2019-05-08 12:01:32
Development of the project logo Websites, patent fillings, videos etc. 2019-05-08 12:01:20

Take a look to the deliverables list in detail:  detailed list of TREGeneration deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREGENERATION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREGENERATION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More